Role of Pseudomonas aeruginosa type III effectors in disease.
about
The trans-kingdom identification of negative regulators of pathogen hypervirulencePouring salt on a wound: Pseudomonas aeruginosa virulence factors alter Na+ and Cl- flux in the lungMicrobiology, genomics, and clinical significance of the Pseudomonas fluorescens species complex, an unappreciated colonizer of humansAssociation between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a reviewIn the absence of effector proteins, the Pseudomonas aeruginosa type three secretion system needle tip complex contributes to lung injury and systemic inflammatory responsesPseudomonas aeruginosa ExoT Induces Atypical Anoikis Apoptosis in Target Host Cells by Transforming Crk Adaptor Protein into a CytotoxinStructural basis of cytotoxicity mediated by the type III secretion toxin ExoU from Pseudomonas aeruginosaStructure of PqsD, a Pseudomonas Quinolone Signal Biosynthetic Enzyme, in Complex with AnthranilateMembrane and Chaperone Recognition by the Major Translocator Protein PopB of the Type III Secretion System of Pseudomonas aeruginosaInterfacial residues of SpcS chaperone affects binding of effector toxin ExoT in Pseudomonas aeruginosa: novel insights from structural and computational studiesExsA and LcrF recognize similar consensus binding sites, but differences in their oligomeric state influence interactions with promoter DNAFull virulence of Pseudomonas aeruginosa requires OprFModulation of Type III Secretion System in Pseudomonas aeruginosa: Involvement of the PA4857 Gene ProductThe ADP-ribosylation domain of Pseudomonas aeruginosa ExoS is required for membrane bleb niche formation and bacterial survival within epithelial cells.The Pseudomonas aeruginosa exoenzyme Y impairs endothelial cell proliferation and vascular repair following lung injury.Injection of Pseudomonas aeruginosa Exo toxins into host cells can be modulated by host factors at the level of translocon assembly and/or activityDiscovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion.Protective effect of DNA vaccine encoding pseudomonas exotoxin A and PcrV against acute pulmonary P. aeruginosa InfectionMutations in the Pseudomonas aeruginosa needle protein gene pscF confer resistance to phenoxyacetamide inhibitors of the type III secretion system.Efflux pumps expression and its association with porin down-regulation and beta-lactamase production among Pseudomonas aeruginosa causing bloodstream infections in BrazilT3SEdb: data warehousing of virulence effectors secreted by the bacterial Type III Secretion System.FimL regulates cAMP synthesis in Pseudomonas aeruginosa.Pseudomonas aeruginosa injects NDK into host cells through a type III secretion system.Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.In vitro and in vivo characterization of the Pseudomonas aeruginosa cyclic AMP (cAMP) phosphodiesterase CpdA, required for cAMP homeostasis and virulence factor regulation.Lipoic acid metabolism in microbial pathogens.Interleukin-8 production by human airway epithelial cells in response to Pseudomonas aeruginosa clinical isolates expressing type a or type b flagellins.Pseudomonas aeruginosa elastase provides an escape from phagocytosis by degrading the pulmonary surfactant protein-A.Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumoniaExoU activates NF-κB and increases IL-8/KC secretion during Pseudomonas aeruginosa infection.Five mechanisms of manipulation by bacterial effectors: a ubiquitous theme.Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens.The Pseudomonas aeruginosa type III translocon is required for biofilm formation at the epithelial barrier.The peptide chain release factor methyltransferase PrmC is essential for pathogenicity and environmental adaptation of Pseudomonas aeruginosa PA14.Hypoxia modulates infection of epithelial cells by Pseudomonas aeruginosa.Type II secretion system of Pseudomonas aeruginosa: in vivo evidence of a significant role in death due to lung infectionDisruption of the endothelial barrier by proteases from the bacterial pathogen Pseudomonas aeruginosa: implication of matrilysis and receptor cleavageSubversion of mucosal barrier polarity by pseudomonas aeruginosaSynthesis and structure-activity relationships of novel phenoxyacetamide inhibitors of the Pseudomonas aeruginosa type III secretion system (T3SS).VE-cadherin cleavage by LasB protease from Pseudomonas aeruginosa facilitates type III secretion system toxicity in endothelial cells.
P2860
Q26782915-3505332A-2BD4-405E-962D-C449488D4CD4Q27001070-D22CDB59-1839-44C0-874F-28565EDF00E6Q27011525-81F27717-2051-4441-83B7-EEC1D53AF1A2Q27013824-8B070836-FF06-4488-9FAE-EA8720C02099Q27300857-DF4A4A9E-0983-413C-9D72-537DEE049AD8Q27319429-8F4DF1AE-B423-4B24-BAD6-2D82169688D5Q27346512-F3134227-F18D-482C-AEB5-1512D70130BBQ27657088-0AE4C644-C6A4-4A94-B63C-BB6EDDAC4E72Q27680731-564C221E-59DF-40EB-A105-08E0496F6023Q27688059-82C5852A-092D-4E36-8833-FAA868E06D3DQ28492815-D3C033EE-005E-4161-8354-5D3D41198833Q28492965-62F9E416-6839-43AA-8D2D-B3BB7457B9E5Q29346770-02263871-D03C-4805-B1FC-D2FFCBACE6ABQ30497320-8FFF9728-EB7C-4B20-9FF3-D265ED0A6DA3Q30578393-A79B8358-D61D-4F0C-89DB-10B1D618B0E3Q31047709-648C8CB6-BCF9-4CF0-A95C-E3732E50A81BQ33533545-D28C0DE3-1932-4562-B295-878CB888BF6DQ33553646-9C1165B0-508D-4734-A74C-DA392A136C34Q33622815-F2691260-EB1C-4F94-B5EF-FDB24A442DCAQ33655586-614A16BC-3E24-4142-B817-32FB8A5E197FQ33755593-913697AC-3FB7-466B-8ECF-04BD3DB340FFQ33802819-72E440F8-D4B5-4979-9754-4D880AE8263AQ33827908-91895898-35D8-4167-B3F9-0418D20EE719Q33836925-EB621640-6C8C-4BEC-8F08-C81D500F2671Q33876925-9D6D8880-3CF9-4F41-A4C9-74CBF3952BFCQ33909117-F23FD016-5A4A-4120-AA5C-B36C5DDA26ECQ34044986-0DD70480-FC19-410F-B17F-8B1F7D84DD30Q34070575-52634655-F11D-4FE9-B049-69E8F29F2349Q34313640-3968068B-77A2-4B58-B0C0-DEFFF4BB4604Q34358987-E57935CA-82D7-46AB-89FB-642BF854E405Q34395262-D5DB0466-474F-4158-8170-1FB2F00418C8Q34447679-2587AC83-F44D-446C-BFF2-A2123AF24F7CQ34466475-8D7D9733-7D06-4628-B341-72342546B6A2Q34528471-06B34F92-27E6-421A-87C1-EC0E63FE2AF3Q34590131-23E6E687-A1C8-44E8-96DA-0C138E780FDDQ34834090-2D2AFE82-220E-497D-A2DD-02B08A2C3462Q34999718-1C2EB83A-F1CD-402A-B902-94EFC7FC928CQ35084653-3253302C-EEF8-48F8-B1C6-E58676F6A245Q35118409-64EE4050-6AAE-4D7E-9FC7-44CB982EAAC6Q35120184-CF7D742C-BD77-4D45-91C2-B2954F3CCA9D
P2860
Role of Pseudomonas aeruginosa type III effectors in disease.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Role of Pseudomonas aeruginosa type III effectors in disease.
@ast
Role of Pseudomonas aeruginosa type III effectors in disease.
@en
Role of Pseudomonas aeruginosa type III effectors in disease.
@nl
type
label
Role of Pseudomonas aeruginosa type III effectors in disease.
@ast
Role of Pseudomonas aeruginosa type III effectors in disease.
@en
Role of Pseudomonas aeruginosa type III effectors in disease.
@nl
prefLabel
Role of Pseudomonas aeruginosa type III effectors in disease.
@ast
Role of Pseudomonas aeruginosa type III effectors in disease.
@en
Role of Pseudomonas aeruginosa type III effectors in disease.
@nl
P1476
Role of Pseudomonas aeruginosa type III effectors in disease.
@en
P2093
Joanne Engel
Priya Balachandran
P356
10.1016/J.MIB.2008.12.007
P577
2009-01-23T00:00:00Z